Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas

References

• Kewalramani T, Zelenetz AD, Hedrick EE, et al High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000;96:2399–2404.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Lifton R, Constine LS, et al Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997;19:883–890.
   PubMed Web of Science ®Google Scholar
• Vose JM, Zhang MJ, Rowlings PA, et al Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406–413.
   PubMed Web of Science ®Google Scholar
• Nademanee A, O'Donnell MR, Snyder DS, et al High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995;85:1381–1390.
   PubMed Web of Science ®Google Scholar
• Alousi AM, Saliba RM, Okoroji GJ, et al Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 2008;142:786–792.
   PubMed Web of Science ®Google Scholar
• Belhadj K, Delfau-Larue MH, Elgnaoui T, et al Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol 2004;15:504–510.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, et al Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927–1932.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C. In vivo purging and relapse prevention following ASCT. Bone Marrow Transplant 2002;29(Suppl. 1):S5–S9.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba RM, Hosing C, et al Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005;23:2240–2247.
   PubMed Web of Science ®Google Scholar
• Neumann F, Harmsen S, Martin S, et al Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma. Ann Hematol 2006;85:530–534.
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Hagemeister F, et al A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310–314.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635–2642.
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chaperot L, et al In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949–954.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754–758.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, et al Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9:5866–5873.
   PubMed Web of Science ®Google Scholar
• Ho AD, Haas R, Wulf G, et al Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. Blood 1990;75:203–212.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Martin H, Wassmann B, et al Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 1998;22:625–630.
   PubMed Web of Science ®Google Scholar
• Young DA, Lowe LD, Clark SC. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 1990;145:607–615.
   PubMed Web of Science ®Google Scholar
• Liljefors M, Nilsson B, Mellstedt H, Frodin JE. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2008;57:379–388.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002;29:303–312.
   PubMed Web of Science ®Google Scholar
• Cartron G, Zhao-Yang L, Baudard M, et al Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008;26:2725–2731.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Fisher RI, Leblanc M, et al Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 2008;111:4048–4054.
   PubMed Web of Science ®Google Scholar
• Katsanis E, Anderson PM, Filipovich AH, et al Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. Blood 1991;78:1286–1291.
   PubMed Web of Science ®Google Scholar
• Margolin KA, Van Besien K, Wright C, et al Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant 1999;5:36–45.
   PubMedGoogle Scholar
• Eisenbeis CF, Grainger A, Fischer B, et al Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 2004;10:6101–6110.
   PubMed Web of Science ®Google Scholar
• Gluck WL, Hurst D, Yuen A, et al Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10:2253–2264.
   PubMed Web of Science ®Google Scholar
• Khan KD, Emmanouilides C, Benson DM Jr, et al A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:7046–7053.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Oki Y, Pro B, Fayad LE, et al Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008;112:831–836.
   PubMed Web of Science ®Google Scholar
• Kline J, Subbiah S, Lazarus HM, van Besien K. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant 2008;41:505–513.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Nimer SD, Zelenetz AD, et al Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;32:673–679.
   PubMed Web of Science ®Google Scholar
• Galimberti S, Marasca R, Caracciolo F, et al The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002;29:581–587.
   PubMed Web of Science ®Google Scholar
• Josting A, Sieniawski M, Glossmann JP, et al High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005;16:1359–1365.
   PubMed Web of Science ®Google Scholar
• Leonard BM, Hetu F, Busque L, et al Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998;91:331–339.
   PubMed Web of Science ®Google Scholar
• Oyan B, Koc Y, Ozdemir E, et al High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma 2006;47:1545–1552.
   PubMed Web of Science ®Google Scholar
• Brugger W, Hirsch J, Grunebach F, et al Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004;15:1691–1698.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Negrin RS, Blume KG, et al Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777–783.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Hari P, Carreras J, et al Pre-transplant rituximab therapy is associated with improved progerssion-free and overall survival in patients undergoing autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma (DLBCL). Blood 2007;110(Suppl. 1): (Abstract 19).
   Google Scholar
• Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006;17(Suppl. 4):iv31–iv32.
   PubMedGoogle Scholar
• Cairoli R, Grillo G, Tedeschi A, D'Avanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 2004;89:361–363.
   PubMed Web of Science ®Google Scholar
• Lemieux B, Tartas S, Traulle C, et al Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:921–923.
   PubMed Web of Science ®Google Scholar
• Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997;89:3951–3959.
   PubMed Web of Science ®Google Scholar
• Robinson N, Benyunes MC, Thompson JA, et al Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Bone Marrow Transplant 1997;19:435–442.
   PubMed Web of Science ®Google Scholar
• Burns LJ, Weisdorf DJ, DeFor TE, et al IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003;32:177–186.
   PubMed Web of Science ®Google Scholar
• van Besien K, Margolin K, Champlin R, Forman S. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. Cancer J Sci Am 1997;3(Suppl. 1):S54–S58.
   PubMed Web of Science ®Google Scholar
• Van Besien K, Mehra R, Wadehra N, et al Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2004;10:386–394.
   PubMed Web of Science ®Google Scholar
• Lauria F, Raspadori D, Ventura MA, et al Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation. Bone Marrow Transplant 1996;18:79–85.
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants. Cancer J Sci Am 1997;3(Suppl. 1):S59–S67.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Neuberg D, Gribben JG, et al Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002;117:828–834.
   PubMed Web of Science ®Google Scholar
• Bashey A, Donohue M, Liu L, et al Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion 2007;47:2153–2160.
   PubMed Web of Science ®Google Scholar
• Mollee P, Pereira D, Nagy T, et al Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant 2002;30:273–278.
   PubMed Web of Science ®Google Scholar
• Morton J, Morton A, Bird R, Hutchins C, Durrant S. Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leuk Res 1997;21:21–27.
   PubMed Web of Science ®Google Scholar